Bioxcel Therapeutics, Inc.
A biopharmaceutical company that turns already-approved drugs into new treatments, using AI to "re-innovate" existing medicines. Its lead product, IGALMI, is a small dissolvable film placed under the tongue that calms sudden agitation in people with schizophrenia or bipolar disorder. Founded in 2017 and based in New Haven, Connecticut, the company skipped traditional venture funding and went straight to the public markets the following year — with a name that blends "bio" with a nod to accelerating drug development.
Granted 68.4K · Sold 19.4K
Granted 26.6K · Sold 6.6K
Granted 26.6K · Sold 6.8K
Granted 26.6K · Sold 6.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Mehta VimalCEO and President, Director · 6 transactions | +9.8% | 550.3K | 68.4K | — | 19.4K |
| Rodriguez JavierSee Remarks · 6 transactions | +295% | 26.8K | 26.6K | — | 6.6K |
| Steinhart Richard IChief Financial Officer · 6 transactions | +300.4% | 26.3K | 26.6K | — | 6.8K |
| Yocca FrankChief Scientific Officer · 6 transactions | +306.2% | 26.2K | 26.6K | — | 6.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -39.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.